For the quarter ending 2025-09-30, CTKB had $17,810K increase in cash & cash equivalents over the period. -$4,555K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenue, net | 139,352 | - |
| Cost of sales (excluding stock-based compensation) | 63,219 | - |
| Amortization - license & ip expense | 1,455 | - |
| Sales (excluding stock-based compensation) | 24,646 | - |
| Marketing (excluding stock-based compensation) | 8,221 | - |
| Research and development (excluding stock-based compensation) | 23,401 | - |
| General and administrative (excluding stock-based compensation) | 34,140 | - |
| Stock-based compensation expense | 19,059 | - |
| Other segment items | -12,326 | - |
| Net loss | -5,478 | -16,985 |
| Depreciation and amortization | 1,918 | 3,765 |
| Amortization of operating lease-right-of use assets | 1,142 | 2,107 |
| Stock-based compensation | 5,638 | 13,420 |
| Loss on disposal of property and equipment | -102 | -253 |
| Provision for (benefit from) credit losses | 50 | 52 |
| Provision for excess and obsolete inventory | 132 | 335 |
| Deferred income taxes | -2,627 | -2,392 |
| Loss on investments, accretion, and amortization, net | - | -3,108 |
| Gain on investments, accretion, and amortization, net | -4,461 | - |
| Interest expenses for accretion of the legal settlement liabilities | 141 | 292 |
| Trade accounts receivable | 587 | -7,101 |
| Inventories | 2,222 | 5,073 |
| Prepaid expenses and other assets | -1,114 | 419 |
| Trade accounts payable | 588 | 1,169 |
| Accrued expenses and other liabilities | -1,409 | 670 |
| Legal settlement liabilities | -252 | -588 |
| Operating lease liabilities | -1,079 | -2,197 |
| Deferred revenue | 284 | 1,581 |
| Net cash (used in) provided by operating activities | -3,898 | -17 |
| Purchases of marketable securities | -59,624 | -141,423 |
| Proceeds from maturities of marketable securities | 79,200 | 136,906 |
| Proceeds from sale of property and equipment | 1 | 56 |
| Purchase of property and equipment | 657 | 2,426 |
| Purchase of intangible assets | -2 | 76 |
| Net cash provided by (used in) investing activities | 18,920 | -6,961 |
| Repayment of loan | 145 | 1,660 |
| Proceeds from employee stock purchase plan | 0 | 703 |
| Payments for taxes related to net share settlement of equity awards | 171 | 231 |
| Proceeds from issuance of common stock under employee stock plans | 137 | 103 |
| Proceeds from line of credit | 2,091 | 2,075 |
| Payments for repurchase of shares | -29 | 15,137 |
| Net cash used in financing activities | 1,941 | -14,147 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 846 | -2,149 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | 17,810 | -23,275 |
| Cash and cash equivalents at beginning of period | 98,745 | - |
| Cash and cash equivalents at end of period | 93,281 | - |
Cytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. (CTKB)